PHAXIAM Therapeutics S.A.
PHAXIAM Therapeutics S.A., a clinical-stage biopharmaceutical company, focuses on developing bacteriophage-based therapies for severe resistance infections in France. The company develops and commercializes red cell-based therapies for cancers and orphan diseases. It develops anti-infectious therapies based on the use of bacteriophages (phages) to treat infections caused by Escherichia coli (E.co… Read more
PHAXIAM Therapeutics S.A. (PHXM) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2024: -0.540x
Based on the latest financial reports, PHAXIAM Therapeutics S.A. (PHXM) has a cash flow conversion efficiency ratio of -0.540x as of June 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-8.34 Million) by net assets (€15.45 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
PHAXIAM Therapeutics S.A. - Cash Flow Conversion Efficiency Trend (2012–2023)
This chart illustrates how PHAXIAM Therapeutics S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
PHAXIAM Therapeutics S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PHAXIAM Therapeutics S.A. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
XGDU
F:XGDU
|
N/A |
|
BLENDER BITES LTD.
F:JL4
|
N/A |
|
UTime Limited
NASDAQ:WTO
|
0.025x |
|
DELPHI WORLD MONEY LIMITED
NSE:DELPHIFX
|
0.057x |
|
GGX Gold Corp
PINK:GGXXF
|
0.054x |
|
Greenwing Resources Ltd
PINK:BSSMF
|
-0.059x |
|
NEWGOLD EXCHANGE TRADED FUND
XNSA:NEWGOLD
|
N/A |
|
BRUNSWICK
BE:BWI
|
0.033x |
Annual Cash Flow Conversion Efficiency for PHAXIAM Therapeutics S.A. (2012–2023)
The table below shows the annual cash flow conversion efficiency of PHAXIAM Therapeutics S.A. from 2012 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | €25.61 Million | €-24.43 Million | -0.954x | +29.97% |
| 2022-12-31 | €23.49 Million | €-31.99 Million | -1.362x | +45.55% |
| 2021-12-31 | €22.84 Million | €-57.14 Million | -2.501x | -27.55% |
| 2020-12-31 | €26.54 Million | €-52.05 Million | -1.961x | -285.69% |
| 2019-12-31 | €85.56 Million | €-43.51 Million | -0.508x | -88.53% |
| 2018-12-31 | €145.60 Million | €-39.27 Million | -0.270x | -98.08% |
| 2017-12-31 | €181.42 Million | €-24.70 Million | -0.136x | +72.50% |
| 2016-12-31 | €35.64 Million | €-17.64 Million | -0.495x | -60.07% |
| 2015-12-31 | €47.13 Million | €-14.58 Million | -0.309x | -53.08% |
| 2014-12-31 | €35.82 Million | €-7.24 Million | -0.202x | +57.59% |
| 2013-12-31 | €13.59 Million | €-6.47 Million | -0.476x | -208.76% |
| 2012-12-31 | €-4.03 Million | €621.40K | -0.154x | -- |